These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 31757951)

  • 1. Functional analysis of genetic variants in the high-risk breast cancer susceptibility gene PALB2.
    Boonen RACM; Rodrigue A; Stoepker C; Wiegant WW; Vroling B; Sharma M; Rother MB; Celosse N; Vreeswijk MPG; Couch F; Simard J; Devilee P; Masson JY; van Attikum H
    Nat Commun; 2019 Nov; 10(1):5296. PubMed ID: 31757951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional characterization of 84 PALB2 variants of uncertain significance.
    Wiltshire T; Ducy M; Foo TK; Hu C; Lee KY; Belur Nagaraj A; Rodrigue A; Gomes TT; Simard J; Monteiro ANA; Xia B; Carvalho MA; Masson JY; Couch FJ
    Genet Med; 2020 Mar; 22(3):622-632. PubMed ID: 31636395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Validated Functional Analysis of Partner and Localizer of BRCA2 Missense Variants for Use in Clinical Variant Interpretation.
    Brnich SE; Arteaga EC; Wang Y; Tan X; Berg JS
    J Mol Diagn; 2021 Jul; 23(7):847-864. PubMed ID: 33964450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Missense PALB2 germline variant disrupts nuclear localization of PALB2 in a patient with breast cancer.
    Toh MR; Low CE; Chong ST; Chan SH; Ishak NDB; Courtney E; Kolinjivadi AM; Rodrigue A; Masson JY; Ngeow J
    Fam Cancer; 2020 Apr; 19(2):123-131. PubMed ID: 32048105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional Analysis Identifies Damaging CHEK2 Missense Variants Associated with Increased Cancer Risk.
    Boonen RACM; Wiegant WW; Celosse N; Vroling B; Heijl S; Kote-Jarai Z; Mijuskovic M; Cristea S; Solleveld-Westerink N; van Wezel T; Beerenwinkel N; Eeles R; Devilee P; Vreeswijk MPG; Marra G; van Attikum H
    Cancer Res; 2022 Feb; 82(4):615-631. PubMed ID: 34903604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional Characterization of
    Boonen RACM; Vreeswijk MPG; van Attikum H
    Front Mol Biosci; 2020; 7():169. PubMed ID: 33195396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PALB2 Variants: Protein Domains and Cancer Susceptibility.
    Nepomuceno TC; Carvalho MA; Rodrigue A; Simard J; Masson JY; Monteiro ANA
    Trends Cancer; 2021 Mar; 7(3):188-197. PubMed ID: 33139182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ablation of the Brca1-Palb2 Interaction Phenocopies Fanconi Anemia in Mice.
    Park D; Bergin SM; Jones D; Ru P; Koivisto CS; Jeon YJ; Sizemore GM; Kladney RD; Hadjis A; Shakya R; Ludwig T
    Cancer Res; 2020 Oct; 80(19):4172-4184. PubMed ID: 32732220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterisation of protein-truncating and missense variants in
    Ng PS; Boonen RA; Wijaya E; Chong CE; Sharma M; Knaup S; Mariapun S; Ho WK; Lim J; Yoon SY; Mohd Taib NA; See MH; Li J; Lim SH; Tan EY; Tan BK; Tan SM; Tan VK; van Dam RM; Rahmat K; Yip CH; Carvalho S; Luccarini C; Baynes C; Dunning AM; Antoniou A; van Attikum H; Easton DF; Hartman M; Teo SH
    J Med Genet; 2022 May; 59(5):481-491. PubMed ID: 33811135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compromised BRCA1-PALB2 interaction is associated with breast cancer risk.
    Foo TK; Tischkowitz M; Simhadri S; Boshari T; Zayed N; Burke KA; Berman SH; Blecua P; Riaz N; Huo Y; Ding YC; Neuhausen SL; Weigelt B; Reis-Filho JS; Foulkes WD; Xia B
    Oncogene; 2017 Jul; 36(29):4161-4170. PubMed ID: 28319063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline mutations of PALB2 gene in a sequential series of Chinese patients with breast cancer.
    Zhang K; Zhou J; Zhu X; Luo M; Xu C; Yu J; Deng M; Zheng S; Chen Y
    Breast Cancer Res Treat; 2017 Dec; 166(3):865-873. PubMed ID: 28825143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional evaluation of BRCA2 variants mapping to the PALB2-binding and C-terminal DNA-binding domains using a mouse ES cell-based assay.
    Biswas K; Das R; Eggington JM; Qiao H; North SL; Stauffer S; Burkett SS; Martin BK; Southon E; Sizemore SC; Pruss D; Bowles KR; Roa BB; Hunter N; Tessarollo L; Wenstrup RJ; Byrd RA; Sharan SK
    Hum Mol Genet; 2012 Sep; 21(18):3993-4006. PubMed ID: 22678057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
    Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
    Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A BRCA1 Coiled-Coil Domain Variant Disrupting PALB2 Interaction Promotes the Development of Mammary Tumors and Confers a Targetable Defect in Homologous Recombination Repair.
    Pulver EM; Mukherjee C; van de Kamp G; Roobol SJ; Rother MB; van der Gulden H; de Bruijn R; Lattanzio MV; van der Burg E; Drenth AP; Verkaik NS; Hahn K; Klarenbeek S; de Korte-Grimmerink R; van de Ven M; Pritchard CEJ; Huijbers IJ; Xia B; van Gent DC; Essers J; van Attikum H; Ray Chaudhuri A; Bouwman P; Jonkers J
    Cancer Res; 2021 Dec; 81(24):6171-6182. PubMed ID: 34548335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional Categorization of
    Bouwman P; van der Heijden I; van der Gulden H; de Bruijn R; Braspenning ME; Moghadasi S; Wessels LFA; ; Vreeswijk MPG; Jonkers J
    Clin Cancer Res; 2020 Sep; 26(17):4559-4568. PubMed ID: 32546644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.
    Sato K; Koyasu M; Nomura S; Sato Y; Kita M; Ashihara Y; Adachi Y; Ohno S; Iwase T; Kitagawa D; Nakashima E; Yoshida R; Miki Y; Arai M
    Cancer Sci; 2017 Nov; 108(11):2287-2294. PubMed ID: 28796317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and spectrum of germline rare variants in BRCA1/2 and PALB2 among breast cancer cases in Sarawak, Malaysia.
    Yang XR; Devi BCR; Sung H; Guida J; Mucaki EJ; Xiao Y; Best A; Garland L; Xie Y; Hu N; Rodriguez-Herrera M; Wang C; Jones K; Luo W; Hicks B; Tang TS; Moitra K; Rogan PK; Dean M
    Breast Cancer Res Treat; 2017 Oct; 165(3):687-697. PubMed ID: 28664506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Splicing predictions, minigene analyses, and ACMG-AMP clinical classification of 42 germline PALB2 splice-site variants.
    Valenzuela-Palomo A; Bueno-Martínez E; Sanoguera-Miralles L; Lorca V; Fraile-Bethencourt E; Esteban-Sánchez A; Gómez-Barrero S; Carvalho S; Allen J; García-Álvarez A; Pérez-Segura P; Dorling L; Easton DF; Devilee P; Vreeswijk MP; de la Hoya M; Velasco EA
    J Pathol; 2022 Mar; 256(3):321-334. PubMed ID: 34846068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
    Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
    Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rare, protein-truncating variants in
    Decker B; Allen J; Luccarini C; Pooley KA; Shah M; Bolla MK; Wang Q; Ahmed S; Baynes C; Conroy DM; Brown J; Luben R; Ostrander EA; Pharoah PD; Dunning AM; Easton DF
    J Med Genet; 2017 Nov; 54(11):732-741. PubMed ID: 28779002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.